Mechanically-restricted percutaneous gene therapeutic solutions for heart failure.

针对心力衰竭的机械限制性经皮基因治疗解决方案。

• 批准号: nhmrc : 367630
• 负责人: Dr John Power
• 金额: $ 12.47万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/mechanically-restricted-percutaneous-heart-failure/101293
• 关键词: Mechanically; restricted; percutaneous; gene; therapeutic

We have developed a novel system for the localized delivery of specialised genes to the heart in order to improve contractility and function of a failing heart. Many genes, for reasons of toxicity, clearance, or uptake, require direct delivery to the target region without spillover to the systemic circulation. Our system addresses these issues by isolating the local circulation of the target organ and directly delivering the agent with minimal systemic loss and improved delivery and uptake efficiency, while minimizing potentially dangerous and toxic systemic effects.

我们已经开发了一种新的系统，用于将特定的基因局部输送到心脏，以改善衰竭心脏的收缩能力和功能。许多基因，出于毒性、清除或摄取的原因，需要直接输送到靶区，而不会溢出到体循环。我们的系统通过隔离靶器官的局部循环并以最小的系统损失和提高的递送和摄取效率直接递送药物来解决这些问题，同时将潜在的危险和有毒的全身影响降至最低。